Jefferies analyst Peter Welford in a note to investors wrote that after their lung cancer stumble earlier this month, Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely complicates regulatory discussions for approval of this indication.”
